Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
American Heart Journal, Volume 168, No. 1, Year 2014
Notification
URL copied to clipboard!
Description
Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease. © 2014 Mosby, Inc.
Authors & Co-Authors
Holman, Rury R.
United Kingdom, Oxford
Churchill Hospital
Bethel, M. Angelyn
United Kingdom, Oxford
Churchill Hospital
Chan, Julianna Chung Ngor
Hong Kong
Prince of Wales Hospital Hong Kong
Chiasson, Jean Louis
Canada, Montreal
Centre Hospitalier de L'universite de Montreal
Doran, Zoë
United Kingdom, Oxford
Churchill Hospital
Ge, Junbo
China, Shanghai
Fudan University
Gerstein, Hertzel C.
Canada, Hamilton
Hamilton Health Sciences
Huo, Yong
China, Beijing
Peking University First Hospital
McMurray, John JV
United Kingdom, Glasgow
Glasgow Cardiovascular Research Centre
Ryde´n, Lårs E.
Sweden, Stockholm
Karolinska Universitetssjukhuset
Liyanage, Winitha
United Kingdom, Oxford
Churchill Hospital
Schröder, Stefan
Germany, Berlin
Bayer Pharma ag
Tendera, Michal B.
Poland, Katowice
Slaski Uniwersytet Medyczny w Katowicach
Theodorakis, Michael J.
United Kingdom, Oxford
Churchill Hospital
Tuomilehto, Jaakko O.I.
Austria, Krems an Der Donau
Donau-universität Krems
Finland, Helsinki
Terveyden ja Hyvinvoinnin Laitos
Saudi Arabia, Jeddah
King Abdulaziz University
Yang, Wenying
China, Beijing
China-japan Friendship Hospital
Hu, Dayi
China, Beijing
Peking University People's Hospital
Pan, Changyu
China, Beijing
General Hospital of People's Liberation Army
Statistics
Citations: 49
Authors: 18
Affiliations: 16
Identifiers
Doi:
10.1016/j.ahj.2014.03.021
ISSN:
00028703
e-ISSN:
10976744
Research Areas
Noncommunicable Diseases
Study Design
Randomised Control Trial
Cross Sectional Study